{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:56:58Z","timestamp":1790247418840,"version":"4.1.0"},"reference-count":41,"publisher":"National Academy of Sciences","issue":"21","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":184,"URL":"https:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA163926"],"award-info":[{"award-number":["R01CA163926"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2019,5,21]]},"abstract":"<jats:p>\n                    A major obstacle to curing chronic myeloid leukemia (CML) is the intrinsic resistance of CML stem cells (CMLSCs) to the drug imatinib mesylate (IM). Prosurvival genes that are preferentially expressed in CMLSCs compared with normal hematopoietic stem cells (HSCs) represent potential therapeutic targets for selectively eradicating CMLSCs. However, the discovery of such preferentially expressed genes has been hampered by the inability to completely separate CMLSCs from HSCs, which display a very similar set of surface markers. To overcome this challenge, and to minimize confounding effects of individual differences in gene expression profiles, we performed single-cell RNA-seq on CMLSCs and HSCs that were isolated from the same patient and distinguished based on the presence or absence of BCR-ABL. Among genes preferentially expressed in CMLSCs is\n                    <jats:italic>PIM2<\/jats:italic>\n                    , which encodes a prosurvival serine-threonine kinase that phosphorylates and inhibits the proapoptotic protein BAD. We show that IM resistance of CMLSCs is due, at least in part, to maintenance of BAD phosphorylation by PIM2. We find that in CMLSCs,\n                    <jats:italic>PIM2<\/jats:italic>\n                    expression is promoted by both a BCR-ABL\u2013dependent (IM-sensitive) STAT5-mediated pathway and a BCR-ABL\u2013independent (IM-resistant) STAT4-mediated pathway. Combined treatment with IM and a PIM inhibitor synergistically increases apoptosis of CMLSCs, suppresses colony formation, and significantly prolongs survival in a mouse CML model, with a negligible effect on HSCs. Our results reveal a therapeutically targetable mechanism of IM resistance in CMLSCs. The experimental approach that we describe can be generally applied to other malignancies that harbor oncogenic fusion proteins or other characteristic genetic markers.\n                  <\/jats:p>","DOI":"10.1073\/pnas.1903550116","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T19:55:16Z","timestamp":1557345316000},"page":"10482-10487","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":12,"title":["Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells"],"prefix":"10.1073","volume":"116","author":[{"given":"Leyuan","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnolia L.","family":"Pak","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"St. Louis","sequence":"additional","affiliation":[{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Brehm","sequence":"additional","affiliation":[{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua Julie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605;"},{"name":"Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA 01605"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3017-3298","authenticated-orcid":false,"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl S","year":"1999","unstructured":"Faderl S, . (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164\u2013172.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger MW","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356.","journal-title":"Blood"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock R","year":"2003","unstructured":"Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M (2003) Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics. Ann Intern Med 138:819\u2013830.","journal-title":"Ann Intern Med"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: Evolution of function, regulation, and specificity","volume":"3","author":"Colicelli J","year":"2010","unstructured":"Colicelli J (2010) ABL tyrosine kinases: Evolution of function, regulation, and specificity. Sci Signal 3:re6.","journal-title":"Sci Signal"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman LS","year":"2004","unstructured":"Steelman LS, . (2004) JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189\u2013218.","journal-title":"Leukemia"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia: A review","volume":"34","author":"An X","year":"2010","unstructured":"An X, . (2010) BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia: A review. Leuk Res 34:1255\u20131268.","journal-title":"Leuk Res"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham SM","year":"2002","unstructured":"Graham SM, . (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319\u2013325.","journal-title":"Blood"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin AS","year":"2011","unstructured":"Corbin AS, . (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121:396\u2013409.","journal-title":"J Clin Invest"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake TL","year":"2017","unstructured":"Holyoake TL, Vetrie D (2017) The chronic myeloid leukemia stem cell: Stemming the tide of persistence. Blood 129:1595\u20131606.","journal-title":"Blood"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton A","year":"2012","unstructured":"Hamilton A, . (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119:1501\u20131510.","journal-title":"Blood"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.seminhematol.2010.06.006","article-title":"The elusive chronic myeloid leukemia stem cell: Does it matter and how do we eliminate it?","volume":"47","author":"Carter BZ","year":"2010","unstructured":"Carter BZ, Mak DH, Cortes J, Andreeff M (2010) The elusive chronic myeloid leukemia stem cell: Does it matter and how do we eliminate it? Semin Hematol 47:362\u2013370.","journal-title":"Semin Hematol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia","volume":"24","author":"Sloma I","year":"2010","unstructured":"Sloma I, Jiang X, Eaves AC, Eaves CJ (2010) Insights into the stem cells of chronic myeloid leukemia. Leukemia 24:1823\u20131833.","journal-title":"Leukemia"},{"key":"e_1_3_4_13_2","unstructured":"Ma L Green M (2019) Single cell gene expression profiling in normal HSCs and CML stem cells. NCBI Gene Expression Omnibus. Available at https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE81730. Deposited May 23 2016."},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nature13437","article-title":"Single-cell RNA-seq reveals dynamic paracrine control of cellular variation","volume":"510","author":"Shalek AK","year":"2014","unstructured":"Shalek AK, . (2014) Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature 510:363\u2013369.","journal-title":"Nature"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling","volume":"121","author":"Zhang B","year":"2013","unstructured":"Zhang B, . (2013) Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling. Blood 121:1824\u20131838.","journal-title":"Blood"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: The role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn MC","year":"2011","unstructured":"Nawijn MC, Alendar A, Berns A (2011) For better or for worse: The role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11:23\u201334.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"45358","DOI":"10.1074\/jbc.M307933200","article-title":"The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death","volume":"278","author":"Yan B","year":"2003","unstructured":"Yan B, . (2003) The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 278:45358\u201345367.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0092-8674(95)90411-5","article-title":"Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death","volume":"80","author":"Yang E","year":"1995","unstructured":"Yang E, . (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285\u2013291.","journal-title":"Cell"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","article-title":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia","volume":"123","author":"Keeton EK","year":"2014","unstructured":"Keeton EK, . (2014) AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123:905\u2013913.","journal-title":"Blood"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","article-title":"Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors","volume":"24","author":"Mikkers H","year":"2004","unstructured":"Mikkers H, . (2004) Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24:6104\u20136115.","journal-title":"Mol Cell Biol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda J","year":"2006","unstructured":"Kuroda J, . (2006) Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103:14907\u201314912.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijc.2910230202","article-title":"K562\u2014A human erythroleukemic cell line","volume":"23","author":"Andersson LC","year":"1979","unstructured":"Andersson LC, Nilsson K, Gahmberg CG (1979) K562\u2014A human erythroleukemic cell line. Int J Cancer 23:143\u2013147.","journal-title":"Int J Cancer"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"e00274","DOI":"10.1042\/BSR20150217","article-title":"Control of Pim2 kinase stability and expression in transformed human haematopoietic cells","volume":"35","author":"Adam K","year":"2015","unstructured":"Adam K, . (2015) Control of Pim2 kinase stability and expression in transformed human haematopoietic cells. Biosci Rep 35:e00274.","journal-title":"Biosci Rep"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V94.3.1108.415k07_1108_1112","article-title":"STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells","volume":"94","author":"de Groot RP","year":"1999","unstructured":"de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L (1999) STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 94:1108\u20131112.","journal-title":"Blood"},{"key":"e_1_3_4_25_2","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai K","year":"1996","unstructured":"Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247\u2013254.","journal-title":"Oncogene"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel O","year":"2012","unstructured":"Hantschel O, . (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8:285\u2013293.","journal-title":"Nat Chem Biol"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz C","year":"2011","unstructured":"Hurtz C, . (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208:2163\u20132174.","journal-title":"J Exp Med"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang X","year":"2007","unstructured":"Jiang X, . (2007) Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21:926\u2013935.","journal-title":"Leukemia"},{"key":"e_1_3_4_29_2","first-page":"252ra121","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma L","year":"2014","unstructured":"Ma L, . (2014) A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med 6:252ra121.","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib resistance","volume":"4","author":"Quentmeier H","year":"2011","unstructured":"Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG (2011) BCR-ABL1-independent PI3Kinase activation causing imatinib resistance. J Hematol Oncol 4:6.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato NJ","year":"2004","unstructured":"Donato NJ, . (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64:672\u2013677, and erratum (2004) 64:2306.","journal-title":"Cancer Res"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini A","year":"2017","unstructured":"Giustacchini A, . (2017) Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med 23:692\u2013702.","journal-title":"Nat Med"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni D","year":"2012","unstructured":"Cilloni D, Saglio G (2012) Molecular pathways: BCR-ABL. Clin Cancer Res 18:930\u2013937.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(\u2212) population to imatinib","volume":"40","author":"Airiau K","year":"2012","unstructured":"Airiau K, . (2012) ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(\u2212) population to imatinib. Exp Hematol 40:367\u2013378.e2.","journal-title":"Exp Hematol"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff DJ","year":"2013","unstructured":"Goff DJ, . (2013) A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12:316\u2013328.","journal-title":"Cell Stem Cell"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"33206","DOI":"10.18632\/oncotarget.5091","article-title":"Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias","volume":"6","author":"Curi DA","year":"2015","unstructured":"Curi DA, . (2015) Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget 6:33206\u201333216.","journal-title":"Oncotarget"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ng1094","article-title":"Natural variation in human gene expression assessed in lymphoblastoid cells","volume":"33","author":"Cheung VG","year":"2003","unstructured":"Cheung VG, . (2003) Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 33:422\u2013425.","journal-title":"Nat Genet"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang B","year":"2016","unstructured":"Zhang B, . (2016) Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. J Clin Invest 126:975\u2013991.","journal-title":"J Clin Invest"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder S","year":"2005","unstructured":"Koschmieder S, . (2005) Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105:324\u2013334.","journal-title":"Blood"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: A language for data analysis and graphics","volume":"5","author":"Ihaka R","year":"1996","unstructured":"Ihaka R, Gentleman R (1996) R: A language for data analysis and graphics. J Comput Graph Stat 5:299\u2013314.","journal-title":"J Comput Graph Stat"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1006\/jmcc.1998.0655","article-title":"The statistics of synergism","volume":"30","author":"Slinker BK","year":"1998","unstructured":"Slinker BK (1998) The statistics of synergism. J Mol Cell Cardiol 30:723\u2013731.","journal-title":"J Mol Cell Cardiol"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1903550116","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1903550116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:49:55Z","timestamp":1721231395000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1903550116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,5,21]]}},"alternative-id":["10.1073\/pnas.1903550116"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1903550116","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,8]]},"assertion":[{"value":"2019-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}